Parents of Epileptic Teen Plead For Easier Access to CBD Prescriptions

October 31, 2019 08:00:11

Young Bailey Rankmore suffers from Lennox-Gastaut syndrome, a particularly nasty form of epilepsy that sees him having up to 100 seizures on a daily basis. He is the latest in an increasing number of people in the UK who have used CBD to help manage severe conditions.

His parents, Craig and Rachel Rankmore, have pleaded with the NHS (National Health Service) to make it easier to access prescriptions for medical cannabis. After running out of conventional treatments for their son, they decided to think outside the box, settling on a private CBD prescription when he was fourteen. “He’d have a minimum of 100 big seizures a day,” they said, “the ones people associate with shaking on the floor. We’d seen him in bed, lying there completely lifeless, and we both agreed we’ve got nothing to lose.”

In the episode of Countryfile Diaries, in which they talked about Bailey’s condition, they said that after switching to CBD treatments, they noticed a big difference. Bailey was calmer, and the frequency of his seizures reduced so much that he could now take part in activities that would have been impossible before.

Although a change in the law last year made medical cannabis legal in the UK, doctors have been reluctant to prescribe CBD medication. The claims of cannabidiol’s efficiency are backed by a ton of anecdotal evidence, but little scientific research on the efficacy, safety, and side effects has been carried out. Due to this, most doctors are slow to believe the claims.

This has left the Rankmores in a precarious position. Since they don’t have an NHS prescription, they import medicine from the Netherlands at a high cost. “The bottle of CBD oil you get in Holland is £182 ($234.7). By the time that bottle of oil comes to our pharmacy,” they said,” that bottle of oil becomes £500 ($644.75), and he goes through three bottles of oil a week.”

The Rankmores were among a group of UK parents of children with severe epilepsy who were left in a bind after the body that recommends NHS spending declined to back medical cannabis treatment for children on the health service. According to the National Institute for Health and Care Excellence, there had not been enough evidence at the time to prove that CBD helped patients. The institute called for further research.

A spokesman from the Cardiff and Vale University Health Board said it had been in contact with the Rankmores, adding that they would continue to work with them to best manage his condition in the future.

The Department of Health and Social Care said that “the government is working with the health system, the industry, researchers and others to improve the evidence base for these products so that decisions can be made about public funding, and to provide clinicians with further support and guidance on prescribing these products where clinically appropriate.”

It is unfortunate that patients like Bailey Rankmore have to suffer needlessly when CBD can ease their condition. Experts believe CBD companies like VPR Brands LP (OTCQB: VPRB) and Green Growth Brands Inc. (CSE: GGB) (OTCQB:GGBXF) must be extremely frustrated each time a story like that of the Rankmores comes to light when there is an abundant supply for CBD to help severely ill kids.

About CBDWire

CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published:

Do you have a questions or are you interested in working with CNW? Ask Our Editor

Denver, Colorado
303.498.7722 Office